CreoSG Co.,Ltd.
KKRX:0403502,660.00
KRW
-105.00
(-3.80%)
ISIN
KR7040350001
Return %
Stock
S&P 500
1Y
-17.39
14.20
3Y
-41.02
81.12
5Y
-81.21
68.34
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Sang-Gyun Lee
- Full Time Employees
- 48
- Sector
- Technology services
- Industry
- Packaged software
- Address
- Seoul South Korea
- IPO Date
- Jan 10, 2002
- Website
- creosg.com
- Similar Companies
- Business
- CreoSG Co., Ltd. is a South Korea-based company primarily engaged in the development and provision of financial information technology (IT) solutions and the research and development of biotechnology products and vaccines. The company operates through two main business divisions: IT Solutions and Biotechnology. The IT Solutions division specializes in core banking software, financial package solutions, and systems integration services, providing core banking platforms including the BANCS-K framework across C, Java, and legacy environments; enterprise application frameworks including CuroFrame; modular banking applications for customer information management, deposit taking, lending, foreign exchange processing, and general accounting; regulatory and data management systems, including International Financial Reporting Standards (IFRS) solutions and financial MyData platforms; enterprise resource planning (ERP) software; vehicle management systems (VMS); and comprehensive IT services encompassing cloud migration, systems engineering, application development, IT outsourcing (ITO), and infrastructure maintenance. The Biotechnology division focuses on preventive vaccines and immuno-oncology therapeutics utilizing proprietary viral vector technologies, offering the SUV-MAP (Smart Universal Vaccine Platform) based on recombinant vesicular stomatitis virus (VSV) vectors for rapid vaccine candidate generation; SAV001, a whole-killed genetically modified preventive HIV/AIDS vaccine candidate; Prime-Boost HIV/AIDS vaccine pipelines; hepatitis C virus (HCV) vaccine candidates; infectious disease vaccine pipelines for emerging viral threats; and novel immuno-oncology therapies targeting refractory solid tumors. CreoSG Co., Ltd. primarily serves commercial banks, savings banks, securities firms, insurance carriers, research institutes, government health agencies, and global biopharmaceutical partners across South Korea and international markets. In recent corporate developments, the company changed its name from Curocom Co., Ltd. to CreoSG Co., Ltd. in March 2024 to accelerate its strategic transition into advanced biotechnology; completed the statutory absorption and merger of its biopharmaceutical subsidiary, ImmunoVaxBio Inc., in September 2025 to internalize core vaccine and immunology pipelines; entered into a material transfer agreement (MTA) with Alteogen Inc. to advance novel biopharmaceutical research; progressed the manufacturing of clinical trial materials for U.S. FDA Phase 2 clinical trials of its SAV001 HIV vaccine candidate; engaged in collaborative research projects with the International Vaccine Institute (IVI) and the Korea Disease Control and Prevention Agency (KDCA) for epidemic preparedness vaccines, including Marburg virus antigens; and executed capital restructuring initiatives, including equity rights offerings, convertible bond issuances, and a capital reduction to strengthen its balance sheet. Founded on April 24, 1997, CreoSG Co., Ltd. is headquartered in Seoul, South Korea.